ReviewDie Ophthalmologie2025
[New systemic treatment approaches for malignant eyelid tumors].
Review in Die Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Novel systemic treatment approaches for eye tumors].Die Ophthalmologie · 2025Article
- [Novel systemic treatment approaches for eye tumors].Die Ophthalmologie · 2025Article
- [Novel systemic treatment approaches for eye tumors].Die Ophthalmologie · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant tumors of the eyelids represent a diagnostic and therapeutic challenge. Modern treatment approaches, such as targeted treatment and immunotherapy are becoming increasingly more important, particularly in advanced and metastatic stages; however, these can cause side effects such as fatigue, skin reactions and gastrointestinal complaints, which require close monitoring. An effective treatment option for advanced, metastasized or inoperable basal cell carcinoma is the well-manageable oral treatment with hedgehog inhibitors; however, these innovative, systemic treatment approaches require an individually adapted management, which is determined by an interdisciplinary tumor board and accompanied by a specialized, multiprofessional team to ensure optimal patient care.
Indexed as
Identifiers
40227329What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.